Clinical Trial

Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 10, 2024 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to investigate the efficacy and safety of Sintilimab combined with FOLT versus Sintilimab combined with SOX in patients with locally advanced gastric cancer. The research design is intended to observe the comparison of conversion therapy effects, disease-free survival, R0 resection rate, and safety evaluation between the two groups.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-11.
Trial Details
NCT Number NCT06459921
Lead Sponsor Xijing Hospital
Conditions Neoadjuvant Chemotherapy, Sintilimab, Locally Advanced Gastric Cancer
Enrollment 200 participants
Start Date 2024-12-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-10